{
  "id": 19396034,
  "title": "TriSalus: 3 Key Takeaways for Long-Term Investors",
  "url": "https://urgent.news/2026/11/10/trisalus-3-key-takeaways-for-long-term-investors",
  "topic": "business",
  "section": "Business",
  "published": "2026-11-10T20:56:30.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/earnings/takeaways/2026/11/10/trisalus-3-key-takeaways-for-long-term-investors/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": null,
  "summary": "TriSalus (TLSI -11.49%) reported third-quarter 2026 revenue of $12.9 million, missing internal targets due to sales team productivity delays and shifting treatment patterns. However, the company doubled its sales force to capture a $2.5 billion market for pressure-enabled drug delivery (PEDD), and CMS finalized national pricing for outpatient procedures and PEDD embolization in the physician office setting, providing a clear payment path. Gross margin for the quarter improved to 86%, driven by lower average unit cost of TriNav and continuous manufacturing improvements.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}